Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma

NCT02257242 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT02257242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02257242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
Lead sponsor
Brown University
Phase
Phase 1
Overall status
Completed
Start date
May 10, 2017
Completion date
November 18, 2020
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell, marginal zone, lymphoma, follicular, lymphoma, mantle-cell, lymphoma, non-hodgkin, lymphoma, small-cell, waldenstrom macroglobulinemia